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Most Japanese patients with xeroderma pigmentosum group A (XPA) have the homozygous intron 3 splicing
mutations (AlwNI mutation). Here, we report a Japanese XPA patient, XP79KO, a compound heterozygote with a
newly identiﬁed T to G transversion at splice donor site in intron 1 in one allele, and with the AlwNI mutation in
another allele in the XPA gene. The mutation in intron 1 creates two new abnormal splice sites that resulted in two
types of aberrant mRNA. These abnormal splicings cause frameshifts that make stop codons downstream. No XPA
protein was detected in XP79KO ﬁbroblasts.
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Xeroderma pigmentosum (XP) is an autosomal recessive-
ly inherited disease that is classified into seven genetic
complementation groups, A–G, and a variant type (Kreamer
et al, 1987). Patients with group A XP (XPA, OMIM 278700)
usually show the most severe clinical symptoms among
these groups, and about 50% of the XP patients in Japan
belong to complementation group A (Takebe et al, 1987).
Among Japanese patients with XPA, 80% of them have the
homozygous AlwNI mutation in the XPA gene (Genbank
accession number MN000380) (Tanaka et al, 1990; Satokata
et al, 1992; Nishigori, 1994; Sato et al, 1996).
Case Report
XP79KO, a 6-y-old boy, had presented with severe photo-
sensitivity since 6 mo old and was tentatively diagnosed as
XP at the age of 1 y. He developed freckles on his face at
the age of 2 y. He has never shown neurological symptoms.
No skin cancer had developed under strict sun avoidance.
There was no consanguinity in his parents. His photo irra-
diation test revealed that MED was 200 J per m2 and the
peak time causing erythema delayed up to 72 h after ultra-
violet (UV)B exposure. He and his family gave their consent
for investigating inherited variation of XP genes. The Med-
ical Ethics Committee of Kobe University approved this in-
vestigation, which was conducted in accordance with the
Declaration of Helsinki principles.
Mutations in the XPA Gene in XP79KO
Genomic DNA was extracted from normal and XP79KO-
cultured fibroblasts according to a standard phenol/chrolo-
form protocol. All exons and exon–intron boundaries of the
XPA gene were PCR amplified. At first, we examined the
frequently mutated sites in exons 3, 4, 6 in Japanese pa-
tients with XPA that can be recognized by restriction en-
zymes AlwNI, MseI, and HphI, respectively, as described
(Nishigori et al, 1993). The PCR-RFLP analysis showed that
XP79KO is heterozygous for the AlwNI mutation (data not
shown). Direct sequence analysis showed that the other
undetermined mutation was T to G transversion at the sec-
ond nucleotide in intron 1 (Fig 1a). This mutation was not
found in genomic DNA from 30 non-affected unrelated Jap-
anese individuals or the SNP database network in Japan
(http://snpnet.jst.go.jp/top_e.html). The father of the patient
is heterozygous for the AlwNI site and the mother is het-
erozygous for this intron 1 mutation.
Aberrant Splicing of the XPA Pre-mRNA in
XP79KO Cells
Since this intron 1 mutation disrupts the normal 50
splice donor site of intron 1, we examined the abnormal
splicing in XP79KO cells by RT-PCR. Total RNA extracted
from XP79KO and normal cells was reverse tran-
scribed and amplified using primers (RT-E1F: 50-GAG-
CTAGGTCCTCGGAGTGG-30, RT-E6R: 50-TGAAAAGGAC-
CAATCTAAATTTCC-30) encompassing the entire coding
region of XPA mRNA (Fig 1b). These DNA fragments were
cloned and sequenced. Band I had the normal XPA cDNA
sequence. Band II for XP79KO contained three PCR prod-
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ucts. One was identified as a DNA fragment lacking exon 3,
which was designated as def I I (Satokata et al, 1992), and
the other two were found to be lacking the latter parts of
exon 1, which were named def E1A and def E1B (Fig 1c).
The sizes of the RT-PCR products from def I I, def E1A, and
def E1B were 811, 816, and 822 bp, respectively, and these
products consisted of band II (Fig 1d). Both def E1A and def
E1B caused frameshifts that result in a stop codon at the
fifth triplet of exon 2 (Fig 1c).
No XPA Protein was Detected
in XP79KO Cells
Cell extract was prepared from normal, XP79KO, and
XP101KO cells, which were confirmed to have the ho-
mozygous AlwNI mutation, and separated by SDS-PAGE
(Maniatis et al, 1989). Western blot analysis using two kinds
of anti-XPA protein antibodies showed that two bands of 40
and 38 kDa were detected in normal cells (Fig 2, arrows).
The 38 kDa protein is tentatively considered to be a deg-
radation product of the 40 kDa protein (Miura et al, 1991).
No XPA protein, however, was detected in XP79KO and
XP101KO cells (Fig 2).
Cellular UV Sensitivity and UV-Induced
Unscheduled DNA Synthesis (UDS)
The ability to repair the UV-induced DNA damage was de-
termined by measuring cellular sensitivity to UV by means of
the colony formation assay and the UDS as described (Ni-
shigori et al, 1994). D0 value of both XP79KO and XP101KO
cells was 0.8 J per m2 whereas that of normal cells was 5.0
J per m2. UV-induced UDS in XP79KO cells was 4.75% of
the normal level. Both the post-UV colony-forming ability
and UV-induced UDS of the cells from XP79KO’s mother
showed a normal level.
Figure 1
Point mutation in intron 1 in XP79KO causes abberant splicing, resulting in frameshift in the coding region and stop site downstream. (a)
Sequence of the region around exon 1–intron boundary of XP79KO and a normal individual. T to G transversion in the second base of intron 1 in
XP79KO is schematically shown (star). (b) RT-PCR products from xeroderma pigmentosum group A (XPA) mRNA in normal human and XP79KO. Kb
ladder DNA was used as size markers. (c) Base sequences of the cloned cDNA corresponding to normal and XP79KO mRNAs with codon numbers
(boxed). Underlined codons mean frameshift. Two arrowheads indicate abnormal splice sites. A part of exon 1 in normal sequence is not shown. (d)
A scheme of the aberrant splicing of pre-mRNA from the AlwNI and intron 1 mutation alleles in the XPA gene in XP79KO cells.
NOVEL XPA GENE MUTATION IN A JAPANESE XPA PATIENT 245125 : 2 AUGUST 2005
Discussion
Eighteen mutation sites in the XPA gene in the world have
been identified so far (Tanaka et al, 1993; States et al, 1998).
We found the nineteenth mutation that is the first mutation
around exon 1 of the XPA gene.
The severity of neurological abnormalities in Japanese
patients with XPA correlates with the locations of the mu-
tations. XPA patients with the homozygous AlwNI mutation
(skipping the zinc-finger motif in exon 3) manifest the hear-
ing impairment, which is one of the earliest neurological
symptoms, around the age of 5 y. Around the age of 10 y,
they show weak tendon reflexes and gait disturbance. An
XPA patient with the homozygous HphI mutation (codon
228 nonsense mutation in exon 6) had less severe neuro-
logical manifestations compared with those with the ho-
mozygous AlwNI mutation. This difference can be explained
by the fact that the mutated XPA protein produced from
the homozygous HphI mutation remains zinc-finger domain
(exon 3) intact and is more stable than that from the ho-
mozygous AlwNI mutation (Sato et al, 1987; Miura et al,
1991). At first, we thought that the other undetermined mu-
tation of XP79KO should be located near the 30 end of the
XPA gene that would result in mild clinical manifestations
because he had shown no neurological symptoms at the
age of 6 y. This patient, however, has the novel intron 1
mutation that results in aberrant mRNA splicing and no XPA
protein production. These in vitro data coincide with cellular
repair data such as UV sensitivity test and UV-induced UDS
that were similar to that of XPA patients with the ho-
mozygous AlwNI mutation.
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Figure 2
XPA protein was not detected in XP79KO. Western blot analysis of
normal human, XP79KO and XP101KO cells with mouse monoclonal
(BD Pharmingen, San Diego, California: left panel) and rabbit polyclonal
(Santa Cruz Biotechnology, Santa Cruz, California: right panel) anti-
human xeroderma pigmentosum group A (XPA) antibodies. Horseradish
peroxidase-conjugated secondary antibodies were visualized using an
enzyme chemiluminescence system. Two arrows show the two bands
of human XPA protein. Background (non-specific bands) indicates that
the amount of the loaded extract was approximately equal in the lanes.
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